Proteolysis-targeting chimera-doxorubicin conjugate nanoassemblies for dual treatment of EGFR-TKI sensitive and resistant non-small cell lung cancer.

• Tác giả: Sijun Fan, Hui Jiao, Meijing Li, Junhui Ma, Xiang Ma, Guangya Xiang, Ruixue Zhu
• Ngôn ngữ: eng
• Thông tin xuất bản: England : Acta biomaterialia , 2025
• Bộ sưu tập: NCBI
• ID: 63954

Tóm tắt

Proteolysis-targeting chimeras (PROTACs) have emerged as a promising strategy for targeted protein degradation and drug discovery. However, traditional PROTACs face inherent limitations and may also contribute to induce drug resistance. These challenges have driven the development of innovative strategies to overcome these obstacles. In current study, a PROTAC-DOX conjugates (PDCs) nanoassembly strategy was introduced to enhance tumor-targeting capability and overcome the drawbacks of conventional PROTACs. The designed PDC-S nanoparticles (PDC-S NPs) demonstrated potent anti-tumor activity against drug-resistant strains (IC